Epstein-Barr Virus Specific Immunotherapy / Dana-Farber Cancer Institute 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date:  A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  May 27, 2022   
    P2,  N=18, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jul 21, 2021   
    P2,  N=18, Active, not recruiting, 
    Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022 Trial primary completion date: Jun 2021 --> Dec 2021
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date:  A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Oct 24, 2019   
    P2,  N=20, Active, not recruiting, 
    Trial primary completion date: Dec 2020 --> Jun 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date:  A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jan 10, 2019   
    P2,  N=20, Active, not recruiting, 
    Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jan 30, 2018   
    P2,  N=20, Active, not recruiting, 
    Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Apr 18, 2017   
    P1,  N=28, Completed, 
    Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=10 --> 28 | Trial primary completion date: Jun 2017 --> Jun 2015
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Aug 11, 2016   
    P2,  N=20, Active, not recruiting, 
    Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=10 --> 28 | Trial primary completion date: Jun 2017 --> Jun 2015 Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Aug 11, 2016   
    P=N/A,  N=10, Active, not recruiting, 
    Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Mar 9, 2016   
    P=N/A,  N=10, Active, not recruiting, 
    Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2016 --> Jun 2016
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jun 11, 2015   
    P=N/A,  N=10, Active, not recruiting, 
    Trial primary completion date: Feb 2014 --> Jan 2016 Trial primary completion date: Feb 2014 --> Jan 2016